Akebia Therapeutics Crescita futura
Criteri Future verificati 0/6
Si prevede che Akebia Therapeutics aumenterà gli utili e i ricavi rispettivamente del 20.7% e 2.5% all'anno, mentre si prevede che l'EPS crescerà del 20.8% all'anno.
Informazioni chiave
20.7%
Tasso di crescita degli utili
20.85%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 25.4% |
| Tasso di crescita dei ricavi | 2.5% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 14 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento della narrazione • May 19
AKBA: Kidney Pipeline Advances Will Offset Renal Channel Inventory Adjustments
Narrative Update on Akebia Therapeutics Analysts have trimmed their price target on Akebia Therapeutics stock by $1 to $4, citing a new US Renal Care dosing protocol that they say reduced channel inventory by about $4.5M to $5.0M and contributed to Vafseo revenue recognized in Q4 coming in $5M to $6M lower than they had expected. Analyst Commentary Bullish analysts are framing the recent price target trim as a fine tuning of expectations rather than a shift in the core thesis on Akebia Therapeutics.Articolo di analisi • May 11
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results
There's been a major selloff in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares in the week since it released its...Aggiornamento della narrazione • May 03
AKBA: Kidney Pipeline Progress Will Drive Future Upside Despite Inventory Headwinds
Narrative Update on Akebia Therapeutics Analysts have reduced Akebia Therapeutics' price target by $1 to $4, citing updated expectations for Vafseo revenue after a new US Renal Care dosing protocol and related channel inventory adjustments. Analyst Commentary Bullish analysts appear focused on how recent pricing and dosing updates feed into the long term opportunity for Vafseo, even as they recalibrate near term expectations.
Aggiornamento della narrazione • Apr 19
AKBA: Renal Dosing Reset And Inventory Shift Will Support Future Profitability
Akebia Therapeutics' consensus analyst price target has shifted lower, with moves such as a cut from $5 to $4 at BTIG and a $2 reduction at Piper Sandler as analysts factor in recent Vafseo revenue shortfalls tied to US Renal Care's updated dosing protocol and related channel inventory effects. Analyst Commentary Bearish analysts are reassessing Akebia Therapeutics after Vafseo revenue recognized in Q4 came in at about US$5m to US$6m, which they link to a new US Renal Care protocol and an estimated US$4.5m to US$5m decrease in channel inventory.
Aggiornamento della narrazione • Apr 05
AKBA: Phase 2 Kidney Trial Will Offset Dosing Protocol Revenue Reset
Akebia Therapeutics' Street price targets have been trimmed by analysts, with one firm moving from $5 to $4 as they factor in lower than expected Q4 Vafseo revenue tied to a new US Renal Care dosing protocol and related channel inventory reductions. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential even after trimming price targets.Aggiornamento della narrazione • Mar 22
AKBA: Renal Care Dosing Reset Will Support Stronger Long Term Profitability
Akebia Therapeutics' consensus analyst price target has moved lower to $4 from $5, as analysts factor in recent updates on Vafseo revenue recognition tied to US Renal Care dosing protocols and related channel inventory adjustments. Analyst Commentary Bearish analysts are framing the lower $4 price target as a reflection of execution risk around the Vafseo launch, especially after the new US Renal Care dosing protocol affected how much revenue could be recognized in the quarter.
Nuova narrazione • Mar 13
Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio
Renal anemia is one of the most common complications of chronic kidney disease (CKD). As kidney function declines, the production of erythropoietin (EPO) decreases, resulting in reduced stimulation of red blood cell production in the bone marrow and the development of anemia.Aggiornamento della narrazione • Mar 07
AKBA: Phase 2 Kidney Disease Trial And Dosing Reset Will Drive Upside
Narrative Update Akebia Therapeutics' consensus analyst price target has shifted from about $5 to roughly $4.40, as analysts factor in the recent US Renal Care dosing protocol change and its impact on Vafseo channel inventory and recognized Q4 revenue. Analyst Commentary Recent research updates reflect a mixed read on Akebia Therapeutics, with targets adjusted to roughly US$4, as analysts factor in the new US Renal Care dosing protocol and its effect on Vafseo revenue recognition in Q4.Aggiornamento della narrazione • Feb 21
AKBA: Rare Kidney Pipeline Progress Will Support Stronger Long Term Profitability
Analysts have reduced their Akebia Therapeutics price target by $3, citing a lower fair value estimate, a higher discount rate, and a shift to expectations of declining revenue growth. This is partly offset by a slightly stronger profit margin outlook and a lower assumed future P/E multiple.Aggiornamento della narrazione • Feb 07
AKBA: Phase 2 Kidney Disease Pipeline Progress Will Drive Substantial Upside
Analysts have trimmed their fair value estimate for Akebia Therapeutics from US$5.40 to US$5.00, citing updated assumptions for growth, profitability and a higher future P/E multiple reflected in recent Street research, including the lowered Piper Sandler price target. Analyst Commentary Recent research around Akebia Therapeutics has focused on how updated growth and profitability assumptions feed into valuation, including the trimmed fair value estimate and a reset price target.Aggiornamento della narrazione • Jan 24
AKBA: Rare Kidney Disease Pipeline Progress Will Drive Future Upside
Analysts now set their price target for Akebia Therapeutics at US$6.00, unchanged from the prior US$6.00. This reflects updated assumptions around discount rate, revenue growth, profit margin, and future P/E that largely offset each other in their valuation work.Aggiornamento della narrazione • Jan 10
AKBA: Rare Kidney Pipeline And Anemia Data Will Support Future Upside
Analysts have adjusted their price target on Akebia Therapeutics to US$6.00 from US$6.00, reflecting updated assumptions around the discount rate, expected revenue growth, profit margin and a slightly higher future P/E multiple. What's in the News Akebia dosed the first patient in a Phase 2 randomized, double blind, placebo controlled trial of praliciguat for biopsy confirmed focal segmental glomerulosclerosis.Aggiornamento della narrazione • Dec 26
AKBA: Rare Kidney Pipeline Progress Will Drive Future Share Upside
Analysts have nudged their price target for Akebia Therapeutics slightly higher to 6.00 dollars per share from 6.00 dollars previously, reflecting modestly improved long term assumptions around revenue growth, profit margins, and the companys risk profile. What's in the News Akebia has initiated Phase 2 clinical development of praliciguat for focal segmental glomerulosclerosis, triggering an expected 1.0 million dollar regulatory milestone payment to Cyclerion when the first patient is dosed, anticipated in 2026 (Key Developments).Aggiornamento della narrazione • Dec 12
AKBA: Rare Kidney Franchise Will Drive Future Share Upside Despite Higher Risk
Analysts have reduced their fair value estimate for Akebia Therapeutics from 10.00 dollars to 6.00 dollars, citing a higher perceived risk profile. This is reflected in an increased discount rate and a lower future earnings multiple, even as long term revenue growth and margin expectations edge higher.Aggiornamento della narrazione • Nov 28
AKBA: European Partnership And Clinical Data Will Drive Substantial Upside
Analysts have slightly lowered their price target for Akebia Therapeutics from $5.50 to $5.40, citing updated financial forecasts, as well as expectations for improved profit margins and revenue growth. What's in the News Akebia Therapeutics and Medice amended their License Agreement and granted Medice the right to manufacture Vafseo tablets for anemia in chronic kidney disease patients in Europe.Aggiornamento della narrazione • Nov 13
AKBA: Broad U.S. Launch In 2025 Will Drive Upside Potential
Analysts have lowered their price target for Akebia Therapeutics from $6.80 to $5.50, citing moderated expectations for revenue growth and profitability. What's in the News Akebia Therapeutics presented a post-hoc win odds analysis from the Phase 3 INNO2VATE trials of vadadustat, showing favorable effects of Vafseo compared to darbepoetin alfa on death or hospitalization in dialysis patients.Articolo di analisi • Nov 04
Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive
Unfortunately for some shareholders, the Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) share price has dived 25% in the...Aggiornamento della narrazione • Oct 30
AKBA: Expanding Access in Dialysis Settings Will Drive Future Upside
Analysts have adjusted their price target for Akebia Therapeutics from $7.40 to $6.80. They cite slight shifts in projected valuation metrics and underlying financial assumptions.Articolo di analisi • Aug 10
Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment?
NasdaqCM:AKBA 1 Year Share Price vs Fair Value Explore Akebia Therapeutics's Fair Values from the Community and select...Articolo di analisi • Jun 18
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders would be excited to see that the share price has had a great...Articolo di analisi • May 10
Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Investors in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) had a good week, as its shares rose 4.1% to close at US$2.55...Articolo di analisi • May 04
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 38% Share Price Rise
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders would be excited to see that the share price has had a great...
Nuova narrazione • Apr 28
Vafseo And VALOR Study Will Open New Treatment Markets
Early success of Vafseo and reimbursement coverage expansion likely to drive strong revenue growth and market access.Articolo di analisi • Mar 20
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33%
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have continued their recent momentum with a 33% gain in the last month...Articolo di analisi • Mar 16
Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83
Shareholders of Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) will be pleased this week, given that the stock price is up...Articolo di analisi • Jan 22
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified
Despite an already strong run, Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have been powering on, with a gain of...Articolo di analisi • Nov 08
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%
Despite an already strong run, Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have been powering on, with a gain of...Articolo di analisi • Aug 02
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders are no doubt pleased to see that the share price has bounced 34...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 202 | -28 | -38 | -59 | 4 |
| 12/31/2027 | 160 | -68 | -59 | -72 | 5 |
| 12/31/2026 | 207 | -40 | -31 | -43 | 5 |
| 3/31/2026 | 232 | -21 | 52 | 60 | N/A |
| 12/31/2025 | 236 | -5 | 60 | 68 | N/A |
| 9/30/2025 | 225 | -16 | 32 | 32 | N/A |
| 6/30/2025 | 204 | -36 | -3 | -2 | N/A |
| 3/31/2025 | 185 | -45 | -35 | -35 | N/A |
| 12/31/2024 | 160 | -69 | -41 | -41 | N/A |
| 9/30/2024 | 170 | -46 | -39 | -39 | N/A |
| 6/30/2024 | 174 | -40 | -39 | -39 | N/A |
| 3/31/2024 | 187 | -43 | -25 | -25 | N/A |
| 12/31/2023 | 195 | -52 | -23 | -23 | N/A |
| 9/30/2023 | 194 | -59 | -76 | -76 | N/A |
| 6/30/2023 | 201 | -98 | -35 | -35 | N/A |
| 3/31/2023 | 271 | -58 | -69 | -69 | N/A |
| 12/31/2022 | 292 | -94 | -73 | -73 | N/A |
| 9/30/2022 | 294 | -158 | -81 | -81 | N/A |
| 6/30/2022 | 294 | -163 | -171 | -171 | N/A |
| 3/31/2022 | 221 | -276 | -204 | -204 | N/A |
| 12/31/2021 | 212 | -282 | -253 | -253 | N/A |
| 9/30/2021 | 211 | -299 | -221 | -221 | N/A |
| 6/30/2021 | 222 | -300 | -192 | -192 | N/A |
| 3/31/2021 | 259 | -392 | -92 | -92 | N/A |
| 12/31/2020 | 295 | -385 | -111 | -110 | N/A |
| 9/30/2020 | 308 | -391 | -172 | -172 | N/A |
| 6/30/2020 | 340 | -386 | -136 | -134 | N/A |
| 3/31/2020 | 351 | -268 | -214 | -209 | N/A |
| 12/31/2019 | 335 | -280 | N/A | -257 | N/A |
| 9/30/2019 | 325 | -245 | N/A | -239 | N/A |
| 6/30/2019 | 286 | -217 | N/A | -262 | N/A |
| 3/31/2019 | 234 | -193 | N/A | -215 | N/A |
| 12/31/2018 | 208 | -144 | N/A | -97 | N/A |
| 9/30/2018 | 238 | -68 | N/A | -40 | N/A |
| 6/30/2018 | 227 | -65 | N/A | -82 | N/A |
| 3/31/2018 | 206 | -53 | N/A | -67 | N/A |
| 12/31/2017 | 181 | -74 | N/A | -56 | N/A |
| 9/30/2017 | 92 | -127 | N/A | 56 | N/A |
| 6/30/2017 | 51 | -140 | N/A | 82 | N/A |
| 3/31/2017 | 22 | -154 | N/A | 31 | N/A |
| 12/31/2016 | 2 | -136 | N/A | 58 | N/A |
| 9/30/2016 | N/A | -118 | N/A | -61 | N/A |
| 6/30/2016 | N/A | -101 | N/A | -41 | N/A |
| 3/31/2016 | N/A | -76 | N/A | -27 | N/A |
| 12/31/2015 | N/A | -61 | N/A | -52 | N/A |
| 9/30/2015 | N/A | -51 | N/A | -39 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che AKBA rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che AKBA rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che AKBA rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di AKBA ( 2.5% all'anno) crescerà più lentamente rispetto al mercato US ( 11.9% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di AKBA ( 2.5% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di AKBA è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/31 01:27 |
| Prezzo dell'azione a fine giornata | 2026/05/29 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Akebia Therapeutics, Inc. è coperta da 17 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Julian Harrison | BTIG |
| Michael King | Citizens JMP Securities, LLC |
| Jason Butler | Citizens JMP Securities, LLC |